Bromodomain PHD finger transcription factor (BPTF) plays an important role in chromatin remodeling, but its functional role in tumor progression is incompletely understood. Here we explore the oncogenic effects of BPTF in melanoma. The consequences of differential expression of BPTF were explored using shRNA-mediated knockdown in several melanoma cell lines. Immunoblotting was used to assess the expression of various proteins regulated by BPTF. The functional role of BPTF in melanoma progression was investigated using assays of colony formation, invasion, cell cycle, sensitivity to selective BRAF inhibitors, and in xenograft models of melanoma progression (n = 12 mice per group). The biomarker role of BPTF in melanoma progression was assessed using fluorescence in situ hybridization and immunohistochemical analyses. All statistical tests were two-sided. shRNA-mediated BPTF silencing suppressed the proliferative capacity (by 65.5%) and metastatic potential (by 66.4%) of melanoma cells. Elevated BPTF copy number (mean ≥ 3) was observed in 28 of 77 (36.4%) melanomas. BPTF overexpression predicted poor survival in a cohort of 311 melanoma patients (distant metastasis-free survival P = .03, and disease-specific survival P = .008), and promoted resistance to BRAF inhibitors in melanoma cell lines. Metastatic melanoma tumors progressing on BRAF inhibitors contained low BPTF-expressing, apoptotic tumor cell subclones, indicating the continued presence of drug-responsive subclones within tumors demonstrating overall resistance to anti-BRAF agents. These studies demonstrate multiple protumorigenic functions for BPTF and identify it as a novel target for anticancer therapy. They also suggest the combination of BPTF targeting with BRAF inhibitors as a novel therapeutic strategy for melanomas with mutant BRAF.
17 April 2012 in Proceedings of the National Academy of Sciences
Although melanomas with mutant v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) can now be effectively targeted, there is no molecular target for most melanomas expressing wild-type BRAF. Here, we show that the activation of Pleckstrin homology domain-interacting protein (PHIP), promotes melanoma metastasis, can be used to classify a subset of primary melanomas, and is a prognostic biomarker for melanoma. Systemic, plasmid-based shRNA targeting of Phip inhibited the metastatic progression of melanoma, whereas stable suppression of Phip in melanoma cell lines suppressed metastatic potential and prolonged the survival of tumor-bearing mice. The human PHIP gene resides on 6q14.1, and although 6q loss has been observed in melanoma, the PHIP locus was preserved in melanoma cell lines and patient samples, and its overexpression was an independent adverse predictor of survival in melanoma patients. In addition, a high proportion of PHIP-overexpressing melanomas harbored increased PHIP copy number. PHIP-overexpressing melanomas include tumors with wild-type BRAF, neuroblastoma RAS viral (v-ras) oncogene homolog, and phosphatase and tensin homolog, demonstrating PHIP activation in triple-negative melanoma. These results describe previously unreported roles for PHIP in predicting and promoting melanoma metastasis, and in the molecular classification of melanoma.
16 May 2016 in Proceedings of the National Academy of Sciences
Microphthalmia-associated transcription factor (MITF) plays a critical and complex role in melanocyte transformation. Although several downstream targets of MITF action have been identified, the precise mechanisms by which MITF promotes melanocytic tumor progression are incompletely understood. Recent studies identified an oncogenic role for the bromodomain plant homeodomain finger transcription factor (BPTF) gene in melanoma progression, in part through activation of BCL2, a canonical target of MITF signaling. Analysis of the BPTF promoter identified a putative MITF-binding site, suggesting that MITF may regulate BPTF expression. Overexpression of MITF resulted in up-regulation of BPTF in a panel of melanoma and melanocyte cell lines. shRNA-mediated down-regulation of MITF in melanoma cells was accompanied by down-regulation of BPTF and BPTF-regulated genes (including BCL2) and resulted in reduced proliferative capacity of melanoma cells. The suppression of cell growth mediated by MITF silencing was rescued by overexpression of BPTF cDNA. Binding of MITF to the BPTF promoter was demonstrated using ChIP analysis. MITF overexpression resulted in direct transcriptional activation of BPTF, as evidenced by increased luciferase activity driven by the BPTF promoter. These results indicate that BPTF transduces key prosurvival signals driven by MITF, further supporting its important role in promoting melanoma cell survival and progression. Significance Microphthalmia-associated transcription factor (MITF) is a master regulator of survival of the melanocyte lineage, exerting its effects through a cascade of transcriptional activation by interacting with a consensus DNA-binding sequence on the promoters of target genes. This study found that MITF regulates expression of bromodomain plant homeodomain finger transcription factor (BPTF), which has been recently shown to promote melanoma cell growth and metastasis, and serves as a prognostic marker of survival associated with melanoma. These results suggest that MITF directs its prosurvival program in melanoma cells, at least in part by activating BPTF expression, providing additional insight into the MITF signaling cascade. The participation of BPTF in the MITF pathway suggests a critical role for BPTF in maintaining melanoma cell survival, further supporting its role in melanoma progression.
1 August 2021 in Journal of Investigative Dermatology
Homologous recombination DNA-damage repair (HR-DDR) deficiency has been used to treat patients with various solid tumors with poly(ADP-ribose) polymerase inhibitors (PARPi). However, the clinical characteristics of melanoma patients with HR-DDR gene mutations, and the consequences of PARP inhibition, are poorly understood. We compared commercially-available next-generation sequencing data from 84 melanomas from our institution with a dataset of 1,986 patients, as well as 1,088 patients profiled in cBioportal. 21.4% of patients had ≥1 functional HR-DDR mutation, most commonly involving BRCA1, ARID1A, ATM, ATR, and FANCA. Concurrent NF1, BRAF, and NRAS mutations were found in 39%, 39% and 22% of cases, respectively. HR-DDR gene mutation was associated with high tumor mutational burden (TMB) and clinical response to checkpoint blockade. A higher prevalence of HR-DDR mutations was observed in datasets from Foundation Medicine and TCGA. Treatment of HR-DDR-mutated patient-derived xenograft models of melanoma with PARPi produced significant anti-tumor activity in vivo, and was associated with increased apoptotic activity. RNA sequencing analysis of PARPi-treated tumors indicated alterations in pathways involving extracellular matrix remodeling, cell adhesion and cell cycle progression. Melanomas with HR-DDR mutations represent a unique subset, which are more likely to benefit from checkpoint blockade, and may be targeted with PARPi.
4 June 2018 in Proceedings of the National Academy of Sciences
Significance: The development of targeted therapies represents a major advance in cancer therapy, with its most prominent examples including agents targeting HER2 in breast cancer, EGFR and ALK in lung cancer, and BRAF in melanoma. However, a key challenge confronting such precision medicine approaches concerns the presence of subtypes of each of these three common, lethal solid tumors that lack identified molecular drivers, and are thus not amenable to targeted therapies. Our studies identify a role for pleckstrin homology domain-interacting protein (PHIP) in promoting the progression of “driver-negative” subtypes of these common solid tumors. In addition, they demonstrate a physical interaction between PHIP and an activating histone modification, thereby identifying PHIP as a rational target for the therapy of these solid tumor subtypes.
1 August 2010 in Journal of Investigative Dermatology